San Diego, CA – MeCo Diagnostics has announced that it is presenting at Seed Showcase™ as part of Biotech Showcase™ 2023. This year, registered attendees can view MeCo Diagnostic’s presentation live during the in-person event, and also access the pitch deck online now. With 24×7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.
Dr. Adam Watson, Co-Founder and CEO will be presenting in-person:
Hilton San Francisco – Union Square
Date: Wednesday, January 11 2023
Time: 2:40PM
Track: Franciscan D (Ballroom Level)
“We are eager to provide investors with an interim update on our ongoing partnership with the Spanish National Cancer Research Center (CNIO). Our Phase II clinical biomarker optimization study is underway now, with final results anticipated in Q1 2023,” says Dr. Adam Watson.
MeCo Diagnostics is developing AI-optmized, NGS-powered predictive biomarker technology for early-stage breast & prostate cancer which leverages low-toxicity, FDA-approved, repurposed drugs for mechanical deconditioning therapy (MDT).
“MDT is an emergent application of antifibrotic therapy in which tumors with high-risk mechanical conditioning (i.e., coordinated transcriptional responses to pathological tumor stiffening) are targeted using well-tolerated drugs in the neoadjuvant setting. Our goal is to reduce cancer burden before surgery, leading to higher rates of curative tumor resection and lifelong remission. Our partnership with CNIO has provided the rare opportunity to perform high-value, low-cost ‘reverse translational’ research to optimize our lead asset, the MeCo Score, for early-stage HER2-negative breast cancer patients.
“For the benefit of everyone who pays healthcare insurance premiums, we have committed to repurposing generic-emergent drugs, which will radically decrease the cost of therapy. We have declined 2 offers of co-development from companies developing IND antifibrotics, because we don’t believe that strategy would serve the best interests of cancer patients. Conventional new drug development in oncology is unsustainable due to runaway costs and the friction imposed by bureaucracy; in contrast, we are pioneering a commercially viable, biomarker-enabled strategy to usher in the era of inexpensive, efficient, targeted therapy for cancer, which is unprecedented.”
Seed Showcase, as part of Biotech Showcase, is produced by Demy-Colton and EBD Group, and is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters broad geographical investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.
“We are delighted that MeCo Diagnostics will be joining us in San Francisco and presenting at Seed Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Seed Showcase is a prime occasion for today’s cutting-edge entrepreneurs and motivated investors to come together to discover the potential of technologies that will drive the future of the life science industry.”
ABOUT SEED SHOWCASE
Seed Showcase is part of Biotech Showcase, which is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 15th year, Biotech Showcase is a well-established, highly respected conference featuring multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
ABOUT MECO DIAGNOSTICS
MeCo Diagnostics Holdings, Inc. is a venture-backed, seed-stage startup based in San Diego, CA, developing predictive biomarker technology for breast & prostate cancer to harness low-toxicity, FDA-approved, repurposed drugs for metastasis prevention.
